MARTINGALE ASSET MANAGEMENT L P
Position in BCRX — Biocryst Pharmaceuticals Inc
CIK 936944
BOSTON, MA
Position in BCRX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,425,080
+$1,886,924 QoQ
Shares Held
242,508
+329.0% QoQ
Ownership
0.095%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#90
of 316 holders
Holding Since
Dec 2023
5 quarters on record
Voting authority
Sole 48%
Shared 0%
None 52%
Common Shares in BCRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026MARTINGALE ASSET MANAGEMENT L P holds $52,615,067 across 17 Drug Manufacturers - Specialty & Generic names. BCRX ranks #10 (4.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
69,799 | $11,763,923 | |
| 2 | ALKS |
Alkermes plc.
|
170,004 | $8,908,209 | |
| 3 | AMRX |
Amneal Pharmaceuticals, Inc.
|
283,033 | $4,899,301 | |
| 4 | UTHR |
UNITED THERAPEUTICS Corp
|
7,622 | $4,129,828 | |
| 5 | INDV |
Indivior Pharmaceuticals, Inc.
|
85,564 | $3,510,690 | |
| 6 | SUPN |
Supernus Pharmaceuticals, Inc.
|
74,348 | $3,457,925 | |
| 7 | PCRX |
Pacira BioSciences, Inc.
|
112,025 | $2,842,074 | |
| 8 | ANIP |
Ani Pharmaceuticals Inc
|
30,741 | $2,544,739 |
All Filings in BCRX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,425,080 | 242,508 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $538,156 | 56,529 | Shares | Sole | 2026-05-13 | |
| 2024-06-30 | $334,059 | 54,055 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $226,075 | 44,503 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $96,061 | 16,037 | Shares | Sole | 2024-02-12 | |
| No filing history on record for this holder in this stock. | ||||||